Optimising COVID-19 antiviral use
Research Area Leaders
Description
Antivirals have clear benefits for reducing hospitalisation and deaths caused by COVID-19 infection. Timely access to antivirals in primary care requires awareness of their availability by both patient and treating doctor.
Limited information exists on the impact of antivirals in the largely vaccinated population in Australia. In addition, patterns of the coverage of antivirals and their impact on health outcomes in residential aged care facilities are not systematically tracked.
Projects in this research area investigate antiviral usage and impact in an Australian context to ensure comprehensive delivery of antivirals at the scale required during the pandemic.
Related Projects
Related Publications
- Eligible but missing out: a qualitative study of access to COVID-19 antivirals in Australia
- Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study
- Outcomes of antiviral retreatment for immunocompromised hosts with prolonged Severe Acute Respiratory Syndrome Coronavirus 2 polymerase chain reaction positivity: A multicenter Australian retrospective case series